Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.
Kidney Int Suppl
; (106): S61-6, 2007 Aug.
Article
em En
| MEDLINE
| ID: mdl-17653213
ABSTRACT
Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Nefropatias Diabéticas
/
Inibidores Enzimáticos
/
Inibidores de Histona Desacetilases
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article